Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) jumped about 19% on Monday morning after the company released preliminary figures showing strong revenue growth for 2025 driven by its lead product, OJEMDA.
The biopharmaceutical group said preliminary 2025 U.S. net product revenue for OJEMDA reached $155.4 million, representing year-on-year growth of 172%. Alongside the update, Day One issued initial guidance for 2026, forecasting U.S. net product revenue of between $225 million and $250 million. At the midpoint, this would imply approximately 53% year-on-year growth. The company attributed the performance to rising patient demand, with prescription volumes totaling 1,394 in the fourth quarter.
“Following remarkable commercial and clinical progress in 2025 and the strategic acquisition of Mersana and our new pipeline program Emi-Le, we’re entering 2026 poised to deliver on our mission and on our growth aspirations,” said Jeremy Bender, CEO of Day One.
For the fourth quarter of 2025, OJEMDA generated net product revenue of about $52.8 million, reflecting roughly 37% growth compared with the third quarter.
Looking ahead, Day One outlined several priorities for 2026. These include meeting its revenue targets by improving treatment persistency and driving new patient starts to support broader adoption of OJEMDA as the standard of care in second-line pediatric low-grade glioma (pLGG). The company also plans to pursue international expansion of OJEMDA through global commercial partnerships.
In parallel, Day One aims to complete enrollment in its pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in first-line pLGG during the first half of 2026. This timeline could support a mid-2027 data readout and a potential regulatory approval in 2028.
The company said it will provide further updates on its strategy and 2026 priorities at the J.P. Morgan Healthcare Conference on January 12.